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Abstract
Long-term contraceptives are a needed measure for 
prevention of unintended pregnancies. Depot 
medroxyprogesterone acetate (Depo-Provera), a long-term 
injectable contraceptive, is particularly useful for 
adolescent women. Despite the widespread use of Depo- 
Provera, limited data exist in the literature on 
continuation rates, especially among adolescents. The 
purpose of this descriptive study was to determine the 
factors which influence the choice and discontinuation of 
Depo-Provera among adolescents. The Health Belief Model 
served as the theoretical framework to guide this study. 
The convenience sample consisted of adolescent females (N 
= 14) . The instrument utilized for the collection of data 
was the McCarter Depo-Provera Questionnaire. Responses to 
the instrument were analyzed using frequency distributions 
and percentages. The majority of the adolescents (93%) in 
this study were satisfied with Depo-Provera. Most of the 
subjects (86%) chose Depo-Provera because they only had to 
remember to get an injection every 3 months. Only 2
111
subjects discontinued use of Depo-Provera and attributed 
discontinuation to physical and menstrual symptoms. 
Conclusions derived from the findings of this study were 
that the majority of the adolescents had used another 
method of birth control, almost half of the adolescents 
had been pregnant, and most of the adolescents had used 
Depo-Provera for 12 months or longer. Recommendations for 
future research are replication of the study with a 
larger, more diverse sample, replication of the study 
without parental consent for participation in the study if 
not required for administration of Depo-Provera, and 
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The United States has the highest rate of adolescent 
pregnancy among industrialized countries (Spitz et al.,
1996). Adolescent pregnancy is a national dilemma that 
transcends the boundaries of socioeconomic class, race, 
and ethnicity. Adolescent motherhood has negative 
consequences for mother and child ("Teen Pregnancy,"
1997). Nearly 60% of all pregnancies in the United States 
are unintended and almost one half of these occurred 
because contraception failed or was not used properly 
(Marble, 1996). Long-term contraceptives are a needed 
measure for prevention of unintended pregnancies. Access 
to effective long-term contraception should be available 
to every woman for prevention of unintended pregnancy, 
particularly the adolescent. This study will explore why 
adolescents choose and discontinue long-term contraception 
with depot medroxyprogesterone acetate (Depo-Provera).
Establishment of the Problem
Young girls who become pregnant are more likely to be 
poor and have limited future possibilities because 70% of 
teenage mothers drop out of high school ("Teen Pregnancy," 
1997). These adolescents are more likely to have more 
children, spend more time as a single parent, and rely 
more heavily on public assistance than those teens who do 
not have children. Pregnant teens are more likely to have 
medical problems during their pregnancy and are less 
likely to seek prenatal care. The children born to teenage 
mothers face many obstacles. Studies have shown that these 
children are likely to do worse in school, have 
poorer health yet receive less health care, are more 
likely to be incarcerated, and have higher rates of 
adolescent childbearing themselves ("Teen Pregnancy,"
1997).
Although there are a number of contraceptive options 
available to adolescents, many adolescents may be 
uninformed about contraceptive choices despite receiving 
sex education in school. Studies have shown that 50% of 
teenage pregnancies occur within 6 months of first sexual 
intercourse and 20% of pregnancies occur within the first 
month (Moriarty, 1997). Some of the available
3
contraceptive methods include condoms, spermicides, oral 
contraceptive pills, Depo-Provera injections, and the 
Norplant system.
Depo-Provera is an injectable contraceptive which was 
approved for use in the United States in late 1992. It has 
been used worldwide for more than 20 years. This hormonal 
injection provides contraceptive protection for up to 3 
months. The contraceptive efficacy of Depo-Provera has 
been well established with an expected failure rate of 
only 0.3% (Moriarty, 1997). Depo-Provera is a reasonably 
affordable method at a cost of approximately $3 0 to $4 0 
per injection. Depo-Provera is a particularly useful 
method for adolescent women who are typically inconsistent 
users of coital-dependent methods or methods which require 
daily use. Often adolescents who are sexually active and 
started on Depo-Provera fail to return at the required 3- 
month intervals for continued protection from unwanted 
pregnancies. Little has been documented about the reasons 
for adolescents' choice of Depo-Provera as a contraceptive 
and the factors which account for discontinuation of Depo- 
Provera. The purpose of this study was to determine the 
factors which influence adolescents' choice of Depo-
Provera and discontinuation of Depo-Provera among 
adolescents.
After reviewing a number of research studies about 
Depo-Provera, Kaunitz (1994) concluded that contraception 
with Depo-Provera may be ideal for women seeking highly 
effective birth control but who experience problems with 
other reversible methods. In reviewing the literature 
Kaunitz found that some women selected Depo-Provera 
because they had (a) difficulty remembering to take oral 
contraceptive pills daily, (b) experienced compliance 
problems with barrier methods, (c) preferred the 
convenience of one injection every 3 months, (d) developed 
estrogen-related side effects when taking oral 
contraceptives, or (e) required the privacy associated 
with Depo-Provera use--no one other than the administering 
health care provider knew that the drug was being used. 
Other women chose Depo-Provera because medical factors 
precluded the use of estrogen-containing oral 
contraceptive agents or because use of concomitant 
medications could possibly reduce the efficacy of oral or 
implantable contraception. The third group of women, for 
whom pregnancy posed unacceptable fetal or maternal risks, 
selected Depo-Provera because of its extremely high
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contraceptive efficacy. Kaunitz (1994) recommended patient 
education and counseling to minimize Depo-Provera use in 
inappropriate candidates, such as women not willing to 
tolerate menstrual changes, women who may wish to conceive 
in the next 1 to 2 years, and those unable or unwilling to 
return every 3 months for repeat injections.
Pinkston-Koenig and Miller (1995) conducted a study 
that sought to determine the prevalence of, indications 
for, and problems associated with the use of Depo-Provera 
in adolescents. They found that less than half of the 
physicians who responded to questionnaires (N = 616) 
offered Depo-Provera as a contraceptive option to 
adolescents.
Problems related to irregular bleeding were involved 
with discontinuation. Little is known about the use of and 
problems with the use of Depo-Provera in adolescents. 
Future investigations into short-term potential problems, 
such as weight gain or mood changes, and long-term 
potential problems, such as osteoporosis, were cited as 
areas for future studies by Pinkston-Koenig and Miller.
Harel, Biro, Kollar, and Rauh (1996) concluded that 
discontinuation of Depo-Provera and Norplant among 
adolescents was largely the result of irregular menstrual
6
bleeding and weight gain. Counseling about potential side 
effects should be provided before initiation of these 
methods and throughout the use of these methods to help 
increase continuation.
Significance to Nursing
Because adolescent pregnancy is a national problem 
and has negative consequences for both the adolescent 
mother and her child, reliable methods of contraception 
should be available. Although there are many contraceptive 
choices available to adolescents, many adolescents are 
often uninformed about contraceptive choices.
Depo-Provera is a very efficacious and cost-effective 
method of birth control. It is particularly useful for 
adolescent women who are typically inconsistent users of 
coital-dependent methods or those which require daily use. 
Yet often, adolescents who are started on Depo-Provera 
fail to return at the required 3-month intervals for 
continued protection from unwanted pregnancies.
Information on appointment compliance can alert the health 
care provider to focus on ways to improve follow-up 
appointments. Little has been documented about the reasons 
for adolescents' choice of Depo-Provera as a contraceptive 
and the factors which account for their discontinuation
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with Depo-Provera. Once the factors which account for 
discontinuation with Depo-Provera are discovered, measures 
can be taken to increase continuation with this method.
Harel et al. (1996) suggested that counseling about 
potential side effects be provided before initiation of 
Depo-Provera and throughout the use of this drug to help 
increase continuation with this method. By discovering the 
factors that influence adolescents' discontinuation with 
Depo-Provera, health care providers can counsel them on 
the potential for these factors and possibly increase 
continuation with this method. By anticipating, 
counseling, and attempting to prevent physical problems 
associated with the use of Depo-Provera, the health care 
provider may be able to increase adolescents' continuation 
with this method. The health care provider should also 
make an effort to increase the use of a barrier method in 
adolescents to prevent sexually transmitted diseases. When 
discontinuation is requested, the health care provider 
should expedite the use of a new contraceptive method in 
an attempt to reduce the high pregnancy rate observed 
among adolescents after discontinuation of Depo-Provera.
Theoretical Framework
The Health Belief Model will provide the theoretical
framework for this study because sociopsychological
variables are used in the explanation of preventive health
behavior. An individual's motivation to act is considered
a function of the expectancy of goal attainment in the
area of health behavior. The Health Belief Model is
concerned with the subjective world of the acting
individual. The assumptions of this theory are as follows :
. . . in order for an individual to take action
to avoid a disease, he would need to believe 
that he was personally susceptible to the 
disease, that the occurrence of the disease 
would at least have moderate severity on some 
component of his life, and that taking a 
particular action would in fact be beneficial by 
reducing his susceptibility to the condition or, 
if the disease occurred, by reducing its 
severity, and that it would not entail 
overcoming important psychological barriers such 
as cost, convenience, pain, and embarrassment.
(Becker, 19974, p. 3)
The Health Belief Model has been shown by current 
research to be a value expectancy approach to explaining 
and predicting health behaviors that go beyond straight 
information giving. This approach can be used to intervene 
in encouraging contraceptive use among teenagers. Because 
contraceptive action involves a preventive health decision 
followed by correct and consistent use, the model may have
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useful applications to both the prevention and compliance 
aspects of contraceptive behavior (Zellman, 1984) . 
Individual perceptions of adolescents related to their 
perceived susceptibility to pregnancy are important. 
Modifying factors include the adolescents' knowledge about 
pregnancy prevention, the types of contraceptives, the 
availability of contraceptives, and the consequences of 
pregnancy. The likelihood of action includes the 
adolescents' perceived benefits of a long-acting 
contraception as well as perceived side effects with the 
use of this type of contraceptive.
Assumptions
The following assumptions were made for this study :
1. Participants will respond honestly to all items on 
the McCarter Depo-Provera Questionnaire.
2. Adolescents use contraception to prevent 
pregnancies.
3. Adolescents' actions to discontinue Depo-Provera 
as a contraception is based on a perceived benefit/side 
effect evaluation.
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Purpose of Jthe Study
The purpose of this study was to determine the 
factors which influence the choice of and discontinuation 
of Depo-Provera among adolescents.
Statement of the Problem
According to Spitz et al. (1996), pregnancy and birth 
rates among teenage girls in the United States are the 
highest of any developing country. There were 95.9 
pregnancies per 1,000 teenage girls between the ages of 15 
and 19 years by 1990 which reflected a 9% increase over 
the last half of the decade (Spitz et al., 1996). A number 
of contraceptive options are available to adolescents.
Some of the available methods include condoms, 
spermicides, oral contraceptive pills, Depo-Provera 
injections, and the Norplant system. Depo-Provera has been 
introduced as a means for long-term contraception. Yet 
adolescents who are sexually active and started on Depo- 
Provera often fail to return at the required 3-month 
intervals for continued protection from unwanted 
pregnancies. Little has been documented about the reasons 
for adolescents' choice of contraceptives and the factors 
which account for their discontinuation with Depo-Provera. 
The purpose of this study was to determine the factors
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which influence choice of and discontinuation of Depo- 
Provera among adolescents.
Research Questions
The two research questions answered as a result of 
this study were as follows :
1. What are the factors identified by adolescents 
that influence the choice of Depo-Provera as a 
contraceptive method?
2. What are the factors identified by adolescents 
that influence discontinuation of Depo-Provera as a 
contraceptive method?
Definition of Terms
For the purpose of this study, the following terms 
were defined :
Factors : the perceived reasons for choosing Depo- 
Provera as a contraceptive and for discontinuation of 
Depo-Provera as identified on the McCarter Depo-Provera 
Questionnaire.
Choice of Depo-Provera: decision by females between 
the ages of 13 and 2 0 years to use Depo Provera as a 
contraceptive method.
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Discontinuation of Depo-Provera: failure to return on 
the prescribed date for intramuscular injection of Depo- 
Provera.
Adolescents : females between the ages of 13 and 2 0 
years who seek contraception with Depo-Provera.
Chapter II 
Review of the Literature
A review of the literature revealed some information 
about the reasons adolescents choose and discontinue Depo- 
Provera. Many of the adolescents who chose Depo-Provera 
did so because of ease of use, cost, privacy, and 
dissatisfaction with oral contraceptive pills. The 
literature indicated that the majority of adolescents who 
discontinue Depo-Provera do so because of perceived 
adverse side effects. Some of the adverse side effects 
cited in the review of the literature included weight 
gain, irregular menstrual cycles, headaches, and mood 
swings.
Cromer, Smith, Blair, Dwyer, and Brown (1994) 
conducted a prospective study to examine adolescents' 
contraceptive choices between long-term contraceptives, 
either 1evonorge s t re1 implant (Norplant) or
medroxyprogesterone acetate (Depo-Provera), and a combined 
oral contraceptive pill (OCP). The researchers established 
a baseline of physical signs and symptoms present before
13
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use of the chosen contraceptive form in order to compare 
these variables among the different groups on a 
longitudinal basis. Cromer et al. (1994) also 
measured perceived satisfaction and continuation rates 
among the users of the different forms of 
contracept ion.
The subjects of this study (N = 199) were adolescent 
females between the ages of 11 and 2 0 years who desired 
contraception. Each subject selected a contraceptive 
method of choice, with 38% selecting OCP, 33% selecting 
Depo-Provera, and 29% selecting Norplant. The subject 
groups ranged in age from 15.2 to 15.7 years.
Socioeconomic status was generally low, with Hoi1ingshead 
scores ranging from 23 + 11 to 26 + 14.5. Of the three 
study groups, 63% to 67% were African-American; the 
remaining participants were Caucasian. Of the 199 
participants, 27% had been pregnant previously, 24% were 
teen parents, and 9% previously had abortions. Of those 
who had pregnancy histories, 68% reported prior use of a 
birth control method, as compared with 33% of the 
remaining girls who had never been pregnant (x̂  = 18.36, p 
< .01). Data were obtained initially and on follow-up
visits at 3 months and 6 months after entering into the
15
study and beginning a regime on the chosen form of 
contraception. Cromer et al. (1994) obtained data through 
an interview and physical examination.
The baseline of physical signs and symptoms was 
established before beginning the study in order to 
accurately determine the signs and symptoms caused by the 
use of one of the three contraceptive forms. Gynecological 
symptoms surveyed before beginning the study were dysuria, 
vaginal discharge, vaginal itch, pelvic pain, and 
menstrual history. The prevalence of sexually transmitted 
diseases (STDs) was also evaluated.
Medical symptoms which have been associated with 
progestin or estrogen therapy were also reviewed to 
establish a baseline. These symptoms included depression, 
fatigue, headache, dizziness, and nausea. Physical 
examination characteristics recorded were mean blood 
pressure, facial acne, previous use of a birth control 
method, and previous reproductive experiences.
The methods of analysis included means and standard 
deviations for the descriptive data as well as analysis 
and t tests for inferential comparisons. Changes in 
occurrence rates of medical and gynecologic symptoms 
before and after initiation of treatment were assessed by
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the use of McNemar's test on data obtained from those 
subjects who returned for follow-up.
In the baseline findings of the gynecological 
symptoms, Cromer et al. (1994) found no significant 
difference in complaints of dysuria, vaginal discharge, 
vaginal itch, pelvic pain, and menstrual history among the 
three groups. The prevalence of STDs in the group who 
chose Depo-Provera was higher than in those who chose 
Norplant or the OCP. No significant differences in the 
frequency of complaints of depression, fatigue, headache, 
dizziness, and nausea were found among the three groups. 
There were no significant differences among the three 
groups on mean blood pressure or facial acne. The group 
who chose Depo-Provera was significantly more likely to 
have used some other form of contraception in the past. 
Those who chose either Norplant or Depo-Provera were 
significantly more likely to have had a reproductive 
experience.
At the end of 3 months, 105 adolescents (Depo- 
Provera, n = 38; Norplant, n = 4 0; OCP, n = 2 7) remained 
in the study, and at the end of 6 months 4 0 adolescents, 
evenly distributed across the three groups, remained in 
the study. Over 8 0% of those treated with either Norplant
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or Depo-Provera had experienced irregular menstrual 
bleeding. Of those who received Depo-Provera, 34% were 
amenorrheic by the end of 3 months, and 60% were 
amenorrheic by the end of 6 months. About one third of the 
Norplant users were amenorrheic at the end of 3 months 
with no increase in this percentage at the end of 6 
months. Irregular bleeding in the Depo-Provera users 
decreased by the end of the 6-month period. Of the 
Norplant users, irregular bleeding occurred in about one 
third of the users at the end of 3 months and remained 
stable at the end of 6 months. Of the adolescents who used 
the OCP, almost 90% experienced regular cycles.
In comparing the gynecologic and medical symptoms, 
only those who returned for follow-up assessments provided 
data for analysis. Cromer et al. (1994) found no 
significant changes in gynecological symptoms, such as 
vaginal discharge, dysuria, vaginal itch, or pelvic pain, 
from the baseline to the follow-up. More of the girls 
taking Depo-Provera (n = 4, 10%) and Norplant (n = 5, 12%) 
as compared with those taking the OCP (n = 2, 7%) had 
occurrences of sexually transmitted diseases at the end of 
the 3-month follow-up.
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Medical symptoms reviewed showed the most common 
complaints among the three groups were depression, 
headache, and fatigue, which were reported more frequently 
among those using Depo-Provera. These results revealed no 
increase in the frequency of complaints related to 
depression, headache, dizziness, or nausea among the three 
groups after initiation of treatment than before 
initiation of treatment. Results of the physical 
examination characteristics showed no significant 
differences among the users of the three forms of 
contraceptives at the 3-month follow-up and at the 6-month 
follow-up.
Compliance with appointments also was calculated 
among the three groups. Appointment compliance was defined 
as the appearance in the clinic within 2 weeks of a 
scheduled appointment without prompting. Compliance with 
appointments at the 3-month follow-up was highest among 
the Depo-Provera users (66%), followed by the OCP users 
(51%), and the Norplant users (49%). At the end of the 6- 
month follow-up the Depo-Provera users (78%) remained the 
most compliant group compared with those using Norplant 
(40%) or the OCP (46%) (%' = 12.23, p < .01).
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Cromer et al. (1994) found that Norplant and Depo- 
Provera are very popular contraceptives for adolescent 
females, especially among those who have used other forms 
of contraception or have had reproductive experiences. The 
researchers stressed the importance of a baseline 
evaluation of signs and symptoms is important to have 
before initiation of therapy in order to better evaluate 
reported signs and symptoms after initiation of therapy. 
Users of Norplant are more likely to experience the side 
effects of nausea and dizziness, whereas Depo-Provera 
users are more likely to experience amenorrhea and 
fatigue. Another finding was that interventions are needed 
to encourage compliance with follow-up appointments in 
those using Norplant and OCP. Cromer et al. (1994) 
recommended that a similar study be conducted on 
adolescents who require confidentiality to determine 
variables that may impact decision making on those 
adolescents without parental guidance.
In another descriptive study conducted by Freda et 
al. (1996), women's responses to Depo-Provera were 
assessed. The population consisted largely of Medicaid 
recipients served by the inner-city facility. Seventy-two 
women who had received the contraceptive in the facility
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were asked a series of questions, including why they chose 
Depo-Provera, the side effects they experienced, if they 
intended to continue its use, and what they would tell a 
friend about Depo-Provera. Freda et al. (1996) hoped to 
better educate other women by learning how women feel 
about this birth control option.
Women who had received at least one injection of 
Depo-Provera in the facility were contacted and 
interviewed by telephone, using a demographic form and a 
14-item questionnaire. The following demographic data were 
obtained; age, race, education, insurance, and marital 
status. Sixty-three percent of the final sample (n = 72) 
were Hispanic, 29% were black, and 8% were white. The mean 
educational level was 11.4 years of completed education. 
The mean age was 2 7.7 years. Seventy-seven percent of the 
sample were on Medicaid, 13% self-paid, and 10% used 
private insurance to pay for their birth control method. 
Sixty percent of the sample were unmarried.
The questionnaire contained questions pertaining to 
the following information : (a) the three main things the
interviewee would tell another woman about Depo-Provera,
(b) reason for choosing Depo-Provera, (c) satisfaction
with Depo-Provera as a method of birth control, (d)
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satisfaction with the information received from the 
doctors or nurses before the first injection, (e) use of 
condoms since using Depo-Provera, (f) number of sexual 
partners in the past 6 months, (g) symptoms considered by 
the user to be side effects of Depo-Provera, (h) whether
the interviewee planned to have another Depo-Provera 
injection, (i) length of time planned to use Depo-Provera, 
and (j) whether the interviewee planned to become pregnant 
again. The respondents in this study were mostly Hispanic 
(63%) and unmarried (60%). At the time of the interview, 
35% had received only one injection and 33% had received 
two injections. Eighteen percent had three, and 14% had 
four injections.
Freda et al. (1996) found that dissatisfaction with 
oral contraceptives was the typical reason given for 
choosing Depo-Provera. Ninety-three percent of the women 
were satisfied with the information they received before 
their first injection. Eighteen percent thought that the 
injectable contraceptive prevented STDs, and 56% reported 
that they never used condoms since using Depo-Provera.
Of the women interviewed, the majority (78%) 
expressed satisfaction with the method and 64% planned to 
continue its use. A scheduled tubal ligation was the most
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common reason provided for termination of Depo-Provera. 
Sixty-five percent of the respondents experienced side 
effects. Amenorrhea, followed by headaches, hair loss, 
irregular periods, and heavy bleeding were the most 
commonly reported side effects of Depo-Provera.
Women offered multiple responses as to why they chose 
this method. Twenty-five percent of the women reported 
forgetting to take the pills as their reason for choosing 
Depo-Provera, which was the most common reason. Other 
typical reported reasons were "dislike of the pills (20 
percent), advice from a doctor or midwife to try Depo- 
Provera (18 percent), the ease and perceived safety of the 
method (18 percent), and the fact that it is used every 
three months (12 percent)" (p. 185). Five respondents 
reported that they had used Depo-Provera in different 
countries and wanted to use it again, and 9 chose to use 
it while they were breast-feeding.
Freda et al. (1996) found that 78% of the respondents 
expressed satisfaction with the method, compared to 22% 
who were not satisfied. The following reasons were given 
for dissatisfaction : "too much bleeding," "bad headaches," 
"pimples on my face," "losing my hair," and "gaining
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weight" (p. 185). Sixty-five percent planned to have 
another injection despite the dissatisfaction rate.
When the respondents were asked what they would tell 
a friend about Depo-Provera, the most common answers to 
this question were "easy," "safe," "don't have to think 
about it for three months," "don't have to worry about 
getting pregnant," "don't get periods all the time," "You 
could gain weight," and "You might lose some hair." "You 
can use it while you're breast-feeding" was one woman's 
response. Unfortunately, 6% responded that "You don't have 
to use condoms" and 18% reported variations of "It 
prevents sex diseases" (p. 185).
Freda et al. (1996) discovered that side effects were 
experienced by 65% of the respondents. The most common 
side effects were no periods (31%), headaches (27%), hair 
loss (27%), irregular periods (22%), and heavy bleeding 
(19%) . Satisfaction with patient education given before 
their first injection was reported by 93% of the women.
Freda et al. (1996) found that the most common reason 
reported for choosing Depo-Provera was forgetting to take 
the oral contraceptive pills. Other reasons were dislike 
of the pills, the ease and perceived safety of Depo- 
Provera, and the fact that it is needed only every 3
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months. The most common reason provided for termination of 
Depo-Provera was a scheduled tubal ligation. More than 
half of the respondents experienced side effects, such as 
amenorrhea, headaches, hair loss, irregular periods, and 
heavy bleeding. More than three quarters of the 
respondents expressed satisfaction with the method and 
planned to continue its use. Unfortunately, 6% responded 
that condom use was not needed with Depo-Provera use, and 
18% reported that Depo-Provera prevents sexually 
transmitted diseases (Freda et al., 1996).
Pinkston-Koenigs and Miller (1995) sought to 
determine the prevalence of, indications for, and problems 
associated with the use of Depo-Provera as a means of 
contraception among adolescents in the United States. The 
researchers believed that the primary reason adolescent 
health care providers hesitated to prescribe Depo-Provera 
was because its use as a contraceptive had not yet been 
approved by the Food and Drug Administration (FDA).
The researchers mailed 1,026 questionnaires to 
physicians in the United States who were members of the 
Society of Adolescent Medicine, the North American Society 
of Pediatric and Adolescent Gynecology, and directors of 
adolescent medicine fellowship programs, but no physician
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was surveyed more than once. A follow-up mailing yielded a 
total response rate of 60% (N = 616). SYSTAT version 5.1 
was used for statistical analysis. The demographic 
characteristics of physicians who prescribed Depo-Provera 
in their practices were compared using chi-square tests at 
a p value of < .05.
Demographic results revealed that "25% of the 
respondents were trained in pediatrics alone, 3 9% in both 
pediatrics and adolescent medicine, and 14% in obstetrics 
and gynecology" (Pinkston-Koenigs & Miller, 1995, p. 348). 
The remainder of the respondents were educated in either 
internal medicine, internal medicine with adolescent 
medicine, family practice, or family practice with 
adolescent medicine. "The majority of those responding 
practiced in a teaching hospital (40%) or were in a 
private practice (29%)" (Pinkston-Koenigs & Miller, 1995, 
p. 348). The respondents had practiced for a mean of 13.7 
years.
Of the respondents, 87% prescribed contraceptives for 
adolescents and 41% (n = 218) reported prescribing Depo- 
Provera. No relationship existed between prescribing Depo- 
Provera while in training and using Depo-Provera in 
practice (x̂  = 3.0, p > .05) . Depo - Provera was more likely
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to be prescribed by obstetricians than pediatricians (p < 
.01). Those respondents (59%) who prescribed 
contraceptives other than Depo-Provera stated that they 
did not include it because of lack of need in their 
practice, the absence of FDA approval, or both.
Of those physicians who prescribed Depo-Provera, 36% 
required their patients to sign informed consent forms. A 
written protocol for Depo-Provera use was reported by 25%. 
Twenty-seven percent said that they prescribed Depo- 
Provera to minors who were not emancipated and without 
parental consent.
Pinkston-Koenigs and Miller (1995) determined the 
physicians prescribed Depo-Provera for three groups : 
exclusively for mentally retarded patients (43%), medical 
conditions precluding estrogen use as well as mentally 
retarded patients (24%), and others, e.g., teen mothers, 
patients with history of poor compliance with other 
contraceptives.
Those providers who prescribed Depo-Provera followed 
an average of seven patients, each on Depo-Provera (SD = 
13.8). Of those followed, 85% continued Depo-Provera use 
beyond 9 months, and 40% continued its use beyond 21 
months. Reasons for patients' discontinuation as reported
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by their physicians were menstrual irregularity (22%), 
loss to follow-up (22%), or both (13%).
Pinkston-Koenigs and Miller (1995) had several 
unanswered questions. These questions dealt with the use 
of Depo-Provera in adolescents. One of the questions was 
to determine if other health care providers, such as nurse 
practitioners or physician assistants, use Depo-Provera in 
ways that differ from the physicians surveyed. Determining 
if physicians not involved in adolescent health care use 
Depo-Provera was another question posed. Other unanswered 
questions included determining if there were different 
indications for Depo-Provera use in adolescents and 
whether the tolerance for side effects was different in 
adolescents. The researchers recommend that more research 
be conducted about the use of Depo-Provera in adolescents.
Pinkston-Koenigs and Miller (1995) concluded that 
less than half of the physicians who responded to the 
questionnaires used Depo-Provera as a contraceptive. 
Problems related to irregular bleeding were involved with 
discontinuation. Little is known about the use of and 
problems with the use of Depo-Provera in adolescents. 
Future investigations into short-term potential problems, 
such as weight gain or mood changes and long-term
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potential problems such as osteoporosis were cited as 
areas for future studies by the researchers.
In another study, Harel, Biro, Kollar, and Rauh 
(1996) sought to examine the reasons for adolescents' 
discontinuation of the long-acting contraceptives, Depo- 
Provera and Norplant, and to assess their experience after 
discontinuation of these methods of birth control. Both of 
these methods are effective, convenient, coitus- 
independent, and require no daily compliance, which makes 
them a desirable alternative for the prevention of teenage 
pregnancy.
Harel et al. (1996) identified a sample of 72 
adolescents in a hospital-based adolescent clinic who 
discontinued one of the long-acting contraceptives. Of 
this sample, 66 adolescent girls agreed to participate in 
the survey. Of this group of girls, 3 5 discontinued use of 
Depo-Provera (Group 1) and 31 discontinued use of Norplant 
(Group 2). All participants were counseled via printed 
material and verbally about contraceptive methods. Each 
received detailed data on their chosen method. During use 
of Depo-Provera and Norplant, the girls were assessed 
every 3 months by their health care provider and 
throughout the 12 months following discontinuation. The
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adolescents were interviewed and a complete physical exam 
was performed at each follow-up visit. If clinically 
appropriate, pelvic exams were performed for cultures 
(gonorrhea and chlamydia) and papanicolaou (pap) smears.
At each visit condom use was encouraged and condoms were 
supplied.
Demographic and psychosocial data, as well as 
reproductive health and menstrual history, were collected 
by the health care providers. A 3-point Likert-type scale 
(very, somewhat, not) was used to report perceived 
satisfaction and concerns with Depo-Provera and Norplant 
use. At initiation and at follow-up visits, body mass 
index (BMI) was calculated. The day of removal for 
Norplant and 3 months after the last injection of Depo- 
Provera were determined to be the dates of discontinuation 
of use for each method. Irregularity of menstrual flow was 
defined as a flow of greater than 7 days, with an interval 
of less than 21 days or greater than 35 days, or the 
presence of intermenstrual spotting. Harel et al. (1996) 
defined a break in contraceptive use as the use of no 
method after discontinuation of Depo-Provera or Norplant 
or adoption of the next method at least one month after
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the date of discontinuation. Approval of the study was 
granted by the institutional review board of the hospital.
Chi-square analysis for categoric variables and 
student's two-tailed h  test for paired and unpaired data, 
as appropriate, were used for comparisons between and 
within groups. Fisher hypergeometric function also was 
used as appropriate. Type I error («) < .05 was considered 
significant. Conception rates were calculated cumulatively 
at monthly intervals. For descriptive data, Harel et al. 
(1996) expressed the results as the mean ±  standard error.
Harel et al. (1996) found that at the initiation of 
Depo-Provera (Group 1) the average age of the adolescents 
was 16.5 ± 0.3 years. The average age at initiation of 
Norplant (Group 2) was 15.8 ±  0.3 years. Seventy percent 
were African-American and the remainder were Caucasian. 
Group 1 BMI was 24.2 ± 0.6, and Group 2 BMI was 24.1 ±
0.9. In Group 1, the adolescents were 4.7 ±  0.3 years 
postmenarchal and 3.4 ±  0.3 years in Group 2 (p = .002) . 
Both groups reported that they were sexually active. The 
mean onset of sexual activity was 14.4 ±  0.2 years in 
Group 1 and 14.1 ± 0.3 years in Group 2. Both groups 
reported mean lifetime sexual activity as 8 ± 1. Forty- 
five percent of the adolescents who chose Norplant had
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been pregnant in the past, and 2 9% of the adolescents had 
a past history of abortion. Of those who chose Depo- 
Provera, only 23% had been pregnant in the past, 17% of 
whom had a past history of abortion.
Of the adolescents who discontinued Depo-Provera, 15% 
stopped after the first injection, 44% after the second 
injection, 23% after the third injection, and 18% after 
the fourth or more injections. Of those who discontinued 
Norplant, only one was removed in the first 6 months of 
use, whereas 23% of removals occurred within the first 
year, 2 9% in the second year, and 48% in the third year of 
use.
Harel et al. (1996) found that half (48% of the Depo- 
Provera users and 52% of the Norplant users) were 
"somewhat" satisfied with their chosen method. Complete 
dissatisfaction was expressed by a substantial minority 
(29% of Depo-Provera users and 35% of the Norplant users). 
Ninety percent of the adolescents in both groups had 
discussed their decision to discontinue the method with 
another person, typically their mother or boyfriend. Only 
17% of the parents from both groups of adolescents were 
reportedly in complete agreement with the decision to 
discontinue the methods.
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Irregular bleeding, weight gain, and mood changes, 
with no statistical difference between the groups, were 
the most common reasons for discontinuation of either 
Depo-Provera or Norplant. Three adolescents from the Depo- 
Provera users and 5 adolescents from the Norplant users 
reported desire for pregnancy as their reason for 
discontinuation. Of these adolescents, two from each group 
said that their partners influenced their choice because 
of a desire for pregnancy.
Prior Norplant users had a reestablishment of regular 
menstrual bleeding significantly earlier (p = .01) than 
those who were prior Depo-Provera users. Eighty-one 
percent of those who were prior Norplant users resumed 
regularity during the first month after discontinuation.
Of those who had used Depo-Provera, only 50% resumed 
regularity during the first month after discontinuation.
Of those who regained menses, the total duration of 
menstrual bleeding during the first month after 
discontinuation was 7.0 ±  2.0 days in the Depo-Provera 
users and 5.0 dt 2.5 days in the Norplant users. Harel et 
al. (1996) found no statistical difference in the total 
days of bleeding between the groups at 2 to 5 months after 
discontinuation. The probable return to ovulation was
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significantly delayed after discontinuation of Depo- 
Provera compared with adolescents who had previously used 
Norplant.
The adolescents who discontinued use of Depo-Provera 
had an increase in BMI of 1.1 Æ 0.3 (p = .0005) (compared 
with initiation, paired t. test, p = .0005) . Those 
adolescents who discontinued Norplant gained 1.3 ±  0.6 in 
their BMI (compared with initiation, paired L test, p =
.03. At 6 months after discontinuation of the methods 
(compared with BMI at discontinuation, paired J t  test, p = 
.01 in Group 1 [Depo-Provera users], and paired t test, p 
= .02 in Group 2 [Norplant users]) there was a further 
significant increase in BMI. Harel et al. (1996) found no 
significant changes in BMI at > 9 months after 
discontinuation of either method.
Sexual activity immediately after discontinuation of 
both these methods was reported by 4 6% of the adolescents 
using Depo-Provera and 36% of the adolescents using 
Norplant. Documentation of sexually transmitted infection 
(STI) occurred in 2 0% of the adolescents using Depo- 
Provera and in 2 0% throughout the follow-up after 
discontinuation. Nine adolescents using Depo-Provera were 
documented as having abnormal pap smears (atypia and
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squamous intraepithélial lesions), and 2 were documented 
after discontinuation as having abnormal pap smears. After 
discontinuation of Norplant, 55% of the adolescents 
reported no change in sexual interest, 26% reported less 
interest, and 19% reported greater sexual interest. More 
frequent sexual intercourse was reported by 48%. After 
discontinuation, 20% of the adolescents reported 
consistent condom use, compared with 3% while using 
Norplant. During their last sexual intercourse only 33% 
reported condom use. Harel et al. (1996) found of the 
adolescents who used Norplant, an STI was documented in 
64% during Norplant use and 32% during follow-up after 
discontinuation of the method. Forty-five percent of the 
adolescents who used Norplant had abnormal Pap smears 
(atypia and squamous intraepithélial lesions) during use 
of the method and 10% after discontinuation.
After discontinuation of Depo-Provera or Norplant, 
only 62% of the adolescents using Depo-Provera and 63% 
using Norplant utilized a new method with no break in 
contraceptive practice. Nonpermanent, less effective 
methods, with the condom being the most popular, were used 
by 3 7% of the Depo-Provera users and 23% of the Norplant 
users. A highly effective method, such as an oral
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contraceptive, was used as their next method by only 2 6% 
of those who used Depo-Provera and 3 9% of those who used 
Norplant. No method of contraception was adopted after 
discontinuation in 26% of the adolescents in who used 
Depo-Provera and 19% of those who used Norplant.
During the follow-up after discontinuation, 7 
adolescents from Group 1 (Depo-Provera users) and 15 from 
Group 2 (Norplant users) had conceived (x̂  = 5.96, p =
.01) . At 12 months after discontinuation, the cumulative 
conception proportion was significantly higher (Fisher 
exact test, p = .01) among the adolescents who 
discontinued Norplant. Prenatal care was initiated by the 
majority of these adolescents during the first trimester.
Only 57% of the adolescents in both groups continued 
to be satisfied with their decision to stop the methods. 
Fifty-one percent of those who discontinued Depo-Provera 
and 3 9% who discontinued Norplant said that they would 
like to reinstate their former methods in the future.
Harel et al. (1996) concluded that discontinuation of 
Depo-Provera and Norplant among adolescents was largely 
the result of irregular menstrual bleeding and weight 
gain. Counseling about potential side effects should be 
provided before initiation of these methods and throughout
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the use of these methods to help increase continuation. 
Health care providers should manage excessive bleeding 
episodes in an attempt to decrease discontinuation with 
these methods. Another potential side effect was a delay 
in the return of ovulatory regular cycles and fertility 
which may persist for several months after discontinuation 
with Depo-Provera. Harel et al. (1996) recommended that 
users of these methods be cautioned that the immediate 
risk for pregnancy after discontinuation is high. The 
health care provider should also make an effort to 
increase the use of a barrier method of contraception in 
adolescents.
In a similar study, Davidson et al. (1997) conducted 
a prospective study among poor and minority women designed 
to investigate rates of Depo-Provera discontinuation and 
subsequent rates of unprotected intercourse and unintended 
pregnancy. The study sample consisted of 4 91 women who 
were selected from three large hospital-based family 
planning clinics serving poor and ethnically diverse 
populations in New York City, Dallas, and Pittsburgh. 
Eligibility criteria were assessed through a waiting room 
screening form. The eligibility criteria were as follows: 
at least 15 years of age, initiating Depo-Provera use, and
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having received contraceptive counseling. All women who 
met the criteria were asked to participate in the study. 
Interviews were conducted with more than 95% of these 
women.
Davidson et al. (1997) conducted subsequent 
interviews by telephone at one year after initiation. A 
sample of 4 02 women was reinterviewed for this analysis 
yielding a rate of 83%. Those lost to follow-up did not 
significantly differ in terms of age, parity, income, 
educational attainment, employment status, or 
race/ethnicity.
Depo-Provera discontinuation rates and unintended 
pregnancy rates following discontinuation were assessed by 
use of life-table analyses. Comparisons between subgroup 
were based on the Wilcoxon-Gehan test. Depo-Provera 
discontinuation was defined as not having an injection 
within 4 months of the prior injection.
Davidson et al. (1997) assessed unintended pregnancy 
rates by use of life-table analyses of the discontinuers 
at risk for unintended pregnancy (defined as those having 
sexual intercourse and not wanting to become pregnant at 
the time of discontinuation). Unintended pregnancies were 
defined as those that occurred within 9 months of
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discontinuation of Depo-Provera in women not wanting to 
become pregnant.
The women were primarily from minority racial and 
ethnic backgrounds (67% Hispanic, 26% African American, 
and 7% white) and were of low socioeconomic status (62% 
had household incomes below $10,000, and 49% did not have 
a high school diploma).
Thirty-one percent of the participants were 
teenagers, and the average age of the sample was 23.4 
years. Sixty-seven percent of the sample reported at least 
two pregnancies, 65% had at least one unintended 
pregnancy, and 53% were teenagers at the time of their 
first delivery.
Davidson et al. (1997) found that within the first 
year of Depo-Provera use, the majority of women 
discontinued use. At 12 months the cumulative life-table 
discontinuation rate was 58%. Fifty-one percent of those 
who discontinued use of Depo-Provera (31% of the sample) 
did so after the first injection. Eighteen percent of 
those who discontinued use of Depo-Provera did so after 
the second injection.
Race/ethnicity and parity had significant effects on 
rates of discontinuation. African Americans had lower
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rates of discontinuation than Hispanics. Those women with 
two or more live births were less likely to discontinue 
Depo-Provera than women with fewer than two births. Other 
characteristics such as age, educational attainment, 
number of unintended pregnancies, intention to have 
additional children, and partner's attitude toward Depo- 
Provera had no significant effect on discontinuation 
rates.
Those who discontinued Depo-Provera use were asked an 
open-ended question about their primary reason for 
discontinuation of the method. The majority attributed 
discontinuation to the side effects of the method rather 
than to the difficulty of returning to the clinic every 3 
months. Three quarters cited either amenorrhea or 
irregular bleeding or other side effects, such as weight 
gain, headaches, mood changes, or acne, as the primary 
reason for discontinuation. However, only 12% cited 
difficulties in returning to the clinic as reason for 
discontinuation. Other reasons cited as the main reason 
for discontinuation were not being sexually active (5%) 
and wanting to become pregnant (4%).
Follow-up of Depo-Provera discontinuers was limited 
to the discontinuers who were at risk for unintended
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pregnancy (i.e., those who were sexually active and did 
not want to become pregnant at the time of 
discontinuation). Subjects who used not being sexually 
active as the "main reason" for discontinuation and those 
who had not had sexual intercourse since discontinuing 
Depo-Provera were eliminated. Those discontinuers who 
listed wanting to become pregnant as the main reason for 
discontinuation or who listed this as a factor in their 
discontinuation decision were also eliminated.
Davidson et al. (1997) found that half of the group 
at risk for pregnancy either did not make the transition 
to a new contraceptive or used a contraceptive only 
occasionally. Thirty-three percent never used a 
contraceptive method during sexual intercourse, 4% rarely 
used birth control, and 13% reported that they sometimes 
used a contraceptive. The remainder (50%) of the at-risk 
group reported always using birth control. Of those who 
reported ever using a contraceptive, the most frequently 
used methods were oral contraceptives (55%) and condoms 
(31%).
Davidson et al. (1997) found that many Depo-Provera 
discontinuers soon experienced an unintended pregnancy. At 
6 months post-Depo-Provera discontinuation the cumulative
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life-table pregnancy rates were 17%, and at 9 months post­
discontinuation the rates were 20%. Educational 
attainment, race/ethnicity, number of unintended 
pregnancies, and intention to have additional children 
were not found to have any significant effects on 
pregnancy rates.
Frequency of contraceptive use and whether or not the 
respondent was a teenager heavily influenced the rates of 
unintended pregnancy. Those women who never, rarely, or 
sometimes used contraception had cumulative 9-month life- 
table pregnancy rates six times higher than those women 
who always used contraception. Furthermore, teenagers were 
at significantly greater risk for unintended pregnancy 
than older women. The consequence of being a teenager and 
never or only occasionally using contraception resulted in 
an alarmingly high 9-month cumulative pregnancy rate of 
53%.
Davidson et al. (1997) concluded that Depo-Provera 
discontinuers were at great risk for an unintended 
pregnancy because they did not make the transition to 
consistent use of another contraceptive. This risk was 
particularly high among teenagers. The majority of women 
reported that they discontinued Depo-Provera because the
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side effects were unacceptable, even after receiving 
proficient and thorough counseling regarding side effects 
of Depo-Provera.
Davidson et al. (1997) recommended development of 
more aggressive procedures for alerting women about 
upcoming Depo-Provera appointments and for identifying and 
contacting women who miss injections as one possible 
solution to the high rates of discontinuation. Follow-up 
also may reduce rates of unintended pregnancies among 
those who discontinue Depo-Provera by reinforcing the need 
for an alternative contraceptive method.
Westfall, Main, and Barnard (1996) conducted a 
similar study to determine one-year continuation rates of 
Depo-Provera among a cohort of women who began using the 
injectable contraceptive between 1993 and 1995. Westfall 
et al. (1996) believed that the information obtained from 
the study was necessary to determine the feasibility and 
cost-effectiveness of Depo-Provera.
Women who received a contraceptive injection between 
January 2, 1993, and March 31, 1995, were provided a 
numerical identifier that allowed tracking over repeat 
visits for Depo-Provera injections. Demographic variables 
included age, race, payment type, and the clinic location.
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Injections were given according to the manufacturer's 
recommended protocol of one injection at least every 3 
months (approximately 14 weeks or 98 days) in every 
clinic. Calculation of continuation rates was based on 
return visits that occurred between 60 and 105 days from 
the previous visit. Injections that occurred prior to or 
up to one week following the 98̂  ̂day after a woman's 
previous injection were considered repeat injections.
After 105 days women who received repeat injections were 
recorded as having discontinued use and considered to be 
at risk for pregnancy and were provided with pregnancy 
tests. If these women reentered the study, the repeat 
injection was recorded as an initial use.
Westfall et al. (1996) calculated overall 
continuation rates using the number of injections for 
which patients were eligible, based on the length of time 
they had been enrolled in the study. The number of women 
eligible for their next injection who actually received it 
was calculated as the intervisit continuation rate. The 
12-month continuation rate was calculated as the product 
of the first three intervisit continuation rates.
The study sample consisted of 5,178 women who 
received Depo-Provera injections. Seventy-nine percent of
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the sample was white, 12% were Hispanic, and the remaining 
9% were black (4%), Asian (3%) , or other (2%) . The 
majority of the sample were between the ages of 23 and 3 0 
years (44.8%), followed by ages 19 and 22 years (25%). 
Eighty-five percent of the women listed method of payment 
as self-pay, while 10% of the women in the sample were 
reimbursed for services through Medicaid.
All women in the study received at least one 
injection. Forty-one percent discontinued use or were lost 
to follow-up after the initial injection. The second 
injection was administered to 2,813 women; of this number, 
35% were lost to follow-up or discontinued use. The third 
injection was received by 1,662 women; of those, 32% 
discontinued or were lost to follow-up. A fourth injection 
was received by 995 women. The mean time between 
injections was 84 days, with a standard deviation of 6.0 
days (the respective median values were 85 and 6.6 days).
Westfall et al. (1996) revealed a one-year 
continuation rate for Depo-Provera users of 23%. Of the 
women who received a first injection, 57% returned for 
their next visit. Between the second and third visits the 
intervisit continuation rate increased to 63% and between
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the third and fourth visits the continuation rate 
increased to 65%.
For visits occurring after the first year of Depo- 
Provera use, intervisit continuation rates were somewhat 
higher. During the first year of the study the mean 
intervisit continuation rate among users was approximately 
62%. Further, 66% of women who received a fourth injection 
went on to receive a fifth, and nearly 68% of those women 
obtained a sixth injection, and over 75% of this group 
received their seventh Depo-Provera injection.
No statistically significant differences were found 
in continuation rates based on clinic site, age, 
ethnicity, or payment type. A sample of approximately 200 
women who discontinued Depo-Provera use after their first 
injection was followed. Difficulty tolerating side effects 
was reported as the main reason for terminating use. Of 
this sample, 12% were reported as lost to follow-up.
Westfall et al. (1996) found that overall 
continuation rates for Depo-Provera in the population 
described here was very low. Only 57% of users returned 
for their second injection, and only 23% of those eligible 
for a full year of contraceptive protection completed all 
four injections. Poor continuation between the first and
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second injection was followed by slightly improved 
intervisit continuation rates across successive intervals.
Westfall et al. (1996) recommended careful 
identification of those women who actually desire long­
term contraception and counseling aimed at side effects as 
important toward improving continuation rates. An 
effective strategy to enhance continuation is reminder 
postcards or telephone calls. These methods might prove 
impractical among younger women who may not want parents 
or partners to know of their contraceptive practices. 
Enhancing access to clinics that provide Depo-Provera 
might also improve continuation rates, especially among 
younger women.
Sangi-Haghpeykar, Poindexter, Bateman, and Ditmore 
(1996) conducted a prospective study to examine method- 
related experiences and acceptability of Depo-Provera 
among women who used this method of birth control for the 
first time. The specific goals of the study were as 
follows : (a) to examine the longitudinal changes in
bleeding patterns and occurrence of side effects, (b) to 
determine Depo-Provera's continuation and failure rates, 
and (c) to delineate reasons for discontinuation of use.
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Sangi-Haghpeykar et al. (1996) surveyed 536 women who 
had decided to use Depo-Provera for the first time at 17 
provider sites in Texas. The research protocol was 
approved by the review boards for human research at all 
participating institutions before data collection. Each 
subject completed a baseline questionnaire after giving 
informed consent. Data on the subject's source of 
information about Depo-Provera, reasons for selecting this 
method, concerns about Depo-Provera, and reproductive and 
contraceptive histories were collected. The project staff 
collected demographic data that was available in patients' 
charts.
Fifty percent of women who received the injection 
were black, 25% were white, and 25% were Hispanic. The 
women who selected Depo-Provera ranged in age from 13 to 
46 years. The mean length of education was 11.9 ±  2.9 
years. Because the majority were seen at public clinics 
serving primarily low-income women, the income level of 
participants was quite low. The mean annual income for the 
group was $5,978. In respect to reproductive 
characteristics, the number of pregnancies for the women 
receiving the injection ranged from 0 to 10. The number of 
births for subjects of this study ranged from 0 to 7. One
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quarter of the sample had never been pregnant, and one 
third had experienced no births. In addition, 32.5% of the 
women reported at least one elective abortion.
Sangi-Haghpeykar et al. (1996) conducted follow-ups 
with the women through three consecutive injections. 
Patients were asked about their experience with Depo- 
Provera during the past 3 months at each follow-up. They 
were asked about any side effects and/or changes in 
bleeding patterns, overall satisfaction with the method, 
and about plans to use the method for the next 3 months. 
The participant's medical records were used to verify 
receipt of each injection.
Information was collected from each subject by way of 
a self-administered questionnaire upon return visit to the 
clinic. The questionnaires were available in English and 
Spanish. Any questions the subjects had concerning the 
questionnaire were responded to by a clinic nurse or staff 
member. If the subjects did not return to the clinic, the 
information was obtained by telephone or mail.
Many women were unable to be assessed for side 
effects, bleeding irregularities, extent of satisfaction 
with Depo-Provera, and future contraceptive plans upon 
discontinuing the use of Depo-Provera because they did not
49
complete the follow-up questionnaires at their return 
visit to the participating clinics and they could not be 
contacted by telephone or mail. However, the medical 
records of all study participants, including women who had 
not completed the follow-up questionnaires, were reviewed 
for receipt of each injection to reach a more precise 
estimate of Depo-Provera's continuation rate. An 
individual who, based on medical records, stopped the use 
of Depo-Provera and switched to another method or to no 
method was defined as a discontinuer.
Groups of interest were compared by Sangi-Haghpeykar 
et al. (1996), using analysis of variance, student t test, 
categorical procedure, and life-table analysis. The 
Wilcoxon signed-rank test was utilized to measure extent 
of satisfaction with Depo-Provera. Furthermore, 
categorical data analysis with repeated measures was used 
to examine changes in reports of side effects and abnormal 
bleeding patterns over time. A p ^ .05 was considered 
significant. SAS System statistical software was utilized 
to perform all analyses.
The questionnaire administered 3 months after the 
first Depo-Provera injection was completed by 463 
participants (86%). Of those who completed the
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questionnaire, 325 (70%) indicated plans to continue with
Depo-Provera for another 3 months ; the remainder were 
opting to discontinue use of the method. The 6-month 
follow-up questionnaire was completed by 285 (88%) of the
women who had chosen to continue use of Depo-Provera. Of 
these women, 226 (79%) said they planned to continue use 
of this method for another 3 months. Of those who 
indicated plans to continue with Depo-Provera, 195 (86%) 
completed the 9-month follow-up questionnaire.
Sangi-Haghpeykar et al. (1996) estimated a method 
failure rate of 0.2 per 100 using life-table analysis. The 
failure rate applies to the entire first year of use, 
since women who received a fourth injection at 9 months 
were contacted and questioned regarding pregnancies during 
the 3 months following that injection.
At each follow-up contact, weight gain was the most 
commonly reported side effect, indicated by 3 8 to 46% of 
the recipients. Another common complaint reported by 
nearly one fifth of the women at each follow-up contact 
was headaches. No side effects associated with the use of 
Depo-Provera was reported by about one third of women 
surveyed. Regarding changes in bleeding pattern, 
amenorrhea was the most frequent complaint. Other commonly
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reported side effects were spotting or irregular bleeding 
(40 to 46%) and longer periods (19 to 26%). Less than 4% 
reported no change in bleeding patterns while using Depo- 
Provera.
Sangi-Haghpeykar et al. (1996) also investigated 
longitudinal changes in bleeding patterns and experience 
of side effects. Weight gain, acne or skin problems, and 
amenorrhea appeared to significantly increase over time (p 
< .001), but complaints of having longer periods decreased
(p < .001).
Ninety-five percent of the original cohort (n = 53 6) 
were successfully followed through medical records for the 
assessment of Depo-Provera's one-year continuation rate. 
Twenty-nine women were lost to follow-up.
Within one year after receiving the first injection 
of Depo-Provera, 377 patients discontinued use, resulting 
in a one-year continuation rate of 28.6% using life-table 
analysis. The cumulative discontinuation rate after 3 
months of use was 36.4%, after 6 months was 54.4%, after 9 
months was 64.6%, and after 12 months was 71.4%.
Women who continued to use Depo-Provera were compared 
with those who discontinued the use of this method. There 
were no observed differences in age, ethnic origin.
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education, number of pregnancies or births, or plans for 
having children in the future. However, those who had used 
Depo-Provera for the entire study period and those who 
indicated plans to continue to use this method at the 
final survey were more likely to be unmarried (82%) than 
those who opted to stop the use of this contraceptive 
(66%) (p < .05).
Method discontinuation was significantly associated 
with concern about the side effects of Depo-Provera before 
receiving the first injection. At 6 months of follow-up, 
women who indicated plans to continue Depo-Provera use 
were less likely to have concerns about the method's side 
effects before the first injection than were those who 
opted to discontinue after 6 months. Complaints about side 
effects associated with previous methods were not related 
to Depo-Provera's discontinuation.
Sangi-Haghpeykar et al. (1996) obtained data 
concerning the one-year continuation rate of Depo-Provera 
through medical records and was acquired for 95% of the 
study cohort. Women who stopped using Depo-Provera were 
significantly less satisfied with the effect of this 
contraceptive on their health and were more likely to 
regret having used it than those who continued to use this
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method (p < .001). In other measures of satisfaction, 
including convenience of the method and expense, the two 
groups were similar. These conclusions were consistent at 
3, 6, and 9 months of follow-up.
Sangi-Haghpeykar et al, (9196) found reports of 
weight gain, headaches, and depression during the first 3 
months of use were significantly more frequent among women 
who stopped Depo-Provera use than among those who 
continued use. In addition, reports of more frequent 
periods were more common among women who discontinued 
Depo-Provera use, whereas women who continued to use this 
contraceptive were more likely to report less frequent 
periods and lighter bleeding. After 6 months of Depo- 
Provera use, women who ceased to use this method cited 
more frequent periods and increased cramping, whereas 
women who continued to use this method were more likely to 
report lighter menstrual bleeding. After 9 months of use, 
frequent complaints of women who ended Depo-Provera use 
were weight gain, nervousness, amenorrhea, and heavier 
bleeding, whereas those who continued to use this method 
reported spotting or irregular bleeding.
The women who continued to use Depo-Provera at each 
follow-up contact were less likely to have experienced
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side effects associated with the use of this method 
compared with those who discontinued use. Women who 
continued to use Depo-Provera after 3 months of use 
reported an average of 1.6 side effects, compared with 2.3 
for those who stopped its use at this time (p < .001) . An 
average of 1.6 side effects was reported by women 
continuing to use Depo-Provera at 6 months, compared with 
2.1 by those who stopped use (p < .05). The average number 
of side effects reported by the two groups at 9 months of 
use was 1.6 and 2.4, respectively (p < .05).
Sangi-Haghpeykar et al. (1996) found that intolerable 
side effects and changes in menstrual bleeding were the 
most frequently reported reasons specified for 
discontinuing use of Depo-Provera. Two to 6% of the women 
who terminated Depo-Provera did so because they wanted a 
child. Reasons for discontinuation of Depo-Provera were 
examined in respect to demographic characteristics and 
reproductive histories. White women and those with a 
greater number of previous pregnancies were significantly 
more likely to stop Depo-Provera because of side effects 
than Blacks and Hispanics or women with less previous 
pregnancies (p < .05). Age, education, marital status, 
change in marital status, and number of live births were
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not related to the reasons cited by women for 
discontinuing the use of Depo-Provera.
Women who discontinued the use of Depo-Provera were 
questioned regarding the contraceptive method they planned 
to use instead of Depo-Provera. The most commonly selected 
method was oral contraceptives followed by condoms. Of the 
women who ended Depo-Provera use between 3 and 10% were 
not planning to use a contraceptive method, and nearly one 
fifth were undecided. The rest planned to use a variety of 
other methods.
Sangi-Haghpeykar et al. (1996) discovered the most 
commonly reported side effects were weight gain and 
headaches, and the most frequently reported changes in 
bleeding pattern were amenorrhea and irregular bleeding. 
Menstrual changes were reported with greater occurrence 
than nonmenstrua1 side effects.
The primary reasons for switching from one method to 
another, or to no method, among women at risk for 
unintended pregnancies were concerns about the potential 
side effects associated with the use of contraceptives and 
the actual experience of side effects. Concerns about 
Depo-Provera's side effects before the first injection 
were associated with Depo-Provera acceptability which was
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consistent with these reports. Sangi-Haghpeykar et al. 
(1996) found that the primary reasons for method 
discontinuation were the effects of this contraceptive on 
health and bleeding patterns. Reasons cited for stopping 
the use of Depo-Provera were weight gain, headaches, 
depression, nervousness, heavier bleeding, more frequent 
periods, increased cramping, and amenorrhea, whereas those 
who continued to use it reported lighter bleeding and less 
frequent periods. In studies of Depo-Provera acceptability 
conducted in other countries, a change in menstrual 
pattern, in particular amenorrhea, was also the main 
reason for Depo-Provera discontinuation.
Marital status also was associated with acceptability 
of Depo-Provera. Of the women who continued use of Depo- 
Provera, a significantly higher proportion were unmarried 
compared with those who stopped use of this method. 
Acceptability and continued use of Depo-Provera among 
unmarried women may have profound implications for the 
occurrence of unintended pregnancies. Unintended 
pregnancies have been reported to be highest among teens, 
minorities, and unmarried women.
Changes in bleeding patterns over time, such as 
polymenorrhea and prolonged bleeding and spotting, have
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been reported to be more frequent after the first 
injection and are gradually replaced by longer cycles, 
less bleeding, and total amenorrhea after repeated 
injections. A significant increase in the reports of 
amenorrhea among subjects who received repeated injections 
was found, whereas reports of longer periods decreased 
with duration of use. Women may be expected to stop use of 
Depo-Provera with repeated injections because amenorrhea 
is not acceptable to many users and appears to be a reason 
for discontinuation. Other nonmenstrua1 complaints that 
increased with continued use were weight gain and acne or 
skin problems. Another cause of Depo-Provera 
discontinuation in the present investigation was weight 
gain.
Sangi-Haghpeykar et al. (1996) observed the one-year 
continuation rate of Depo-Provera to be 28.6%. This is 
considerably lower than Depo-Provera continuation rates 
reported in other countries. Reasons specified by patients 
for stopping the use of Depo-Provera suggest that certain 
aspects of this injectable contraceptive appear to be 
intolerable and lead to discontinuation. Careful patient 
education and counseling of women unwilling to tolerate 
side effects, such as menstrual changes, headaches, or
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weight increases, can minimize the use of Depo-Provera in 
inappropriate candidates. A detailed description of all 
the side effects that are likely to occur should be 
included in information about Depo-Provera. This 
information may help women select a contraceptive that is 
appropriate for their needs and concerns, leading to less 
contraceptive switching, which has been reported to 
increase the risk of unintended pregnancies.
Summary
Depo-Provera was found to be a very popular 
contraceptive choice for adolescent females, especially 
among those who have used other types of contraception or 
who have been pregnant. Although Depo-Provera is safe, 
effective, and obtainable for adolescents, once adolescent 
females are started on Depo-Provera, they often fail to 
return for subsequent injections.
Freda et al. (1996) found that the most common reason 
reported for choosing Depo-Provera was forgetting to take 
the oral contraceptive pills ; however, dissatisfaction 
with oral contraceptives was the typical reason given. 
Other reasons for choosing Depo-Provera were dislike of 
oral contraceptive pills and ease and perceived safety of 
Depo-Provera.
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Common side effects experienced by Depo-Provera users 
included irregular periods, heavy bleeding, amenorrhea, 
headaches, and hair loss. Discontinuation of Depo-Provera 
among adolescents appears to be the result of intolerable 
side effects such as irregular menstrual bleeding and 
weight gain.
Possible methods to increase compliance with Depo- 
Provera include careful patient education and counseling 
about potential side effects. These adolescents should 
also be counseled on the need to use condoms because Depo- 
Provera does not protect against sexually transmitted 
diseases. Enhancing access to clinics that provide Depo- 
Provera may also lead to improved continuation rates. 
Reminder postcards and telephone calls would also be 
beneficial in improving continuation rates as well as 
identifying those adolescents who are discontinuing Depo- 
Provera.
When discontinuation with Depo-Provera has been 
confirmed, the adolescent is at risk for unintended 
pregnancy. Every effort should be made to have the 
adolescent make the transition to another method of 
contraception in an attempt to prevent pregnancy.
Chapter III 
The Method
The purpose of this descriptive study was to 
determine the factors which influence the choice and 
discontinuation of Depo-Provera among adolescents. This 
chapter will describe the research methods used to 
investigate the variables under study. The design, 
population, sample, and setting as well as instrumentation 
and methods of data collection also will be described in 
this chapter.
Design of the Study
A descriptive design was utilized to determine the 
factors which influence the choice of Depo-Provera and 
discontinuation of Depo-Provera as a contraceptive method 
identified by adolescents. A descriptive design is 
utilized to observe, describe, and document aspects of a 
situation as it naturally occurs with no manipulation of 
variables (Polit & Hungler, 1995). Therefore, a
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descriptive design was appropriate for this study as there 
was no manipulation of variables.
The variables of interest were the factors which 
influence adolescents' choice of Depo-Provera as a 
contraceptive method and the factors which influence 
adolescents' discontinuation of Depo-Provera as a 
contraceptive method as measured by the McCarter Depo- 
Provera Questionnaire.
The control variables were the gender and age of the 
participants and method of contraception utilized by the 
participants. Subjects were adolescent females between the 
ages of 13 and 2 0 years who were currently using or had 
used Depo-Provera as a contraceptive.
The extraneous variables included the truthfulness of 
the subjects in completing the questionnaire and were the 
following: the subject's age; race ; previous pregnancies, 
if any; number of living children, if any; other methods 
of birth control used; reasons for choosing Depo-Provera; 
length of time Depo-Provera had been used; reasons for 
discontinuing Depo-Provera, if no longer using it; 
satisfaction with Depo-Provera; and whether consideration 
would ever be given to using Depo-Provera in the future, 
if no longer using Depo-Provera.
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Research Questions
The research questions in this study were as follows:
1. What are the factors that influence the choice of 
Depo-Provera as a contraceptive method by adolescents?
2. What are the factors that influence 
discontinuation of Depo-Provera as a contraceptive method 
by adolescents?
Limitations
The following limitations were identified for this 
study:
1. The small sample size of this study made the 
results or not generalizable.
2. The use of only two clinics in a southeastern 
state made the results ungeneralizable.
3. The population studied included only adolescent 
females between the ages of 13 and 2 0 years.
Setting, Population, and Sample
The setting for this study was a city in the 
Southeast with a population of 33,000 in the city and 
64,000 in the surrounding county. The setting was a 
private pediatric clinic and a State Department of Health 
clinic.
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The population studied was adolescent females who 
were currently using or who had once used Depo-Provera as 
a method of contraception. The convenience sample 
consisted of 100 adolescent females between the ages of 13 
and 2 0 years who were currently using or who had once used 
Depo-Provera as a method of contraception and were willing 
to participate in the study. If the adolescent was 18 
years of age or younger, parental consent was obtained for 
participation in the study.
Methods of Data Collection
This section describes the methods of data 
collection. A description of instrumentation, procedure, 
and data collection are included.
Inst rument at i on. The McCarter Depo-Provera 
Questionnaire which was used in this study was an 11-item, 
researcher-developed questionnaire (see Appendix A ) . The 
McCarter Depo-Provera Questionnaire elicits demographic 
data, such as age, race, number of pregnancies, number of 
living children, and other methods of birth control 
utilized by the subject. Other information obtained on the 
McCarter Depo-Provera Questionnaire included reasons for 
choosing Depo-Provera, reasons for discontinuing Depo- 
Provera, if no longer using this method, and satisfaction
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with Depo-Provera. Also included was an optional question 
to assess three things the subject liked most and three 
things the subject liked least about Depo-Provera. Because 
this tool was developed by the researcher, there is no 
established validity or reliability. Content validity was 
established by a panel of experts who reviewed and 
evaluated the tool.
Procedures. Following approval by the Committee on 
the Use of Human Subjects in Experimentation at 
Mississippi University for Women (see Appendix B), each 
proposed site was contacted by letter (see Appendix C) for 
permission to distribute questionnaires to clientele who 
were currently or had ever utilized Depo-Provera as a 
contraceptive. Packets which included a description of the 
purpose of the study and the participant's written consent 
(see Appendix D), a written consent for a parent or legal 
guardian of subjects younger than 18 years of age (see 
Appendix E), a copy of the questionnaire, along with 
instructions for its completion, and a self-addressed, 
stamped envelope were delivered to each site for mailing 
to each potential subject. To assure anonymity, the 
subject was instructed not to write her name on the 
questionnaire or on the return envelope. The self­
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addressed, stamped envelope was addressed to the 
researcher, the only person who saw the questionnaire. A 
follow-up postcard was mailed to those who had not 
responded within 10 working days after the initial mailing 
(see Appendix F).
Method of Data Analysis
Descriptive statistics were utilized to describe and 
summarize data obtained with respect to demographic 
variables, adolescents' reasons for choosing Depo-Provera, 
their reasons for discontinuing Depo-Provera, and their 
satisfaction with Depo-Provera. Data from each question on 
the McCarter Depo-Provera Questionnaire was analyzed using 
frequency distributions and percentages.
Chapter IV 
The Findings
The purpose of this study was to determine the 
factors which influence the utilization and 
discontinuation of Depo-Provera among adolescents. A 
survey design was implemented for this descriptive study.
A questionnaire was utilized to obtain information from 
adolescent females about their reason for choosing Depo- 
Provera, and, if no longer using Depo-Provera, their 
reasons for discontinuing use. Data from each 
questionnaire were analyzed using frequency distributions 
and percentages. The findings from the study are presented 
in this chapter.
Description of Sample
The sample consisted of adolescent females who 
responded to the questionnaire. A total of 100 
questionnaires was mailed to female adolescents ranging in 
age from 13 years to 20 years who reside in Mississippi. 
Only 14 subjects returned the questionnaire, despite being
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sent a reminder postcard. The composition of the sample by 
age consisted of no 13-year-olds (0%) , no 14-year-olds 
(0%) , two 15-year-olds (14%) , two 16-year-olds (14%) , one 
17-year-old (7%), four 18-year-olds (29%), two 19-year- 
olds (14%), and three 20-year-olds (22%). Eleven subjects 
(79%) were African American, and 3 subjects (22%) were 
Caucasian. Nearly half (43%) of the subjects had 
previously been pregnant. Of the subjects who had been 
pregnant, 4 subjects had been pregnant one time, one 
subject had been pregnant three times, and one subject did 
not specify the number of previous pregnancies. Of those 
subjects who had been pregnant, 4 had one living child, 
one had 3 living children, and one had no living children. 




Demographic Characteristics of the Sample
Characteristic n %
Age (years)
13 0 0 . 0
14 0 0 . 0
15 2 14 . 0
16 2 14 . 0
17 1 7.0
18 4 29.0
19 2 14 .0
20 3 22 .0
Race
Caucasian 3 21.0
African American 11 79. 0
Previous pregnancy
Yes 6 43 . 0
No 8 57 . 0




Not reported 1 7 . 0
Note. N = 14.
Contraceptive history. Eleven of the subjects (79%) 
had used some form of birth control method in the past. Of 
the 11 subjects who had utilized a birth control method, 3 
had used the pill, 3 had used condoms, 4 had used the pill
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and condoms, and one had used Norplant. Those subjects who 
reported previous pregnancies had utilized the following 
methods: the pill (n = 1), condoms (n =2), and both the 
pill and condoms (n = 3). Three subjects (21%) did not 
report using any previous contraceptive methods.
Reasons for choosing Depo-Provera. Thirteen of the 
subjects said they chose Depo-Provera because they only 
had to remember it every 3 months. Three subjects chose 
Depo-Provera because they felt that it was very effective. 
Four subjects chose Depo-Provera because it was 
inexpensive or free. Four subjects selected Depo-Provera 
because no one could tell they were using the method.
Three subjects selected other reasons for choosing Depo- 
Provera and specified, "Don't have to remember to take it 
everyday," "thought I would have less menstruation," and
"sometimes my periods don't come."
Use of Depo-Provera. The majority of the subjects had 
used Depo-Provera for 12 months (36%). Two of the subjects 
(14%) had used Depo-Provera for 36 months. The remaining 
subjects reported the following time lengths of Depo- 
Provera use : 3 months, 4 months, 6 months, 8 months, 9
months, 10 months, and 13 months.
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Two subjects reported that they no longer use Depo- 
Provera, Reasons for discontinuation cited by both 
subjects were physical symptoms and menstrual problems. 
Physical symptoms included nausea, dizziness, weight gain, 
headaches, hair loss, fatigue, breast tenderness, acne, 
skin problems, or facial hair. Menstrual problems included 
vaginal discharge, irregular periods, spotting between 
periods, or no period.
Half of the subjects (50%) stated being very 
satisfied with Depo-Provera. Six subjects (43%) were 
somewhat satisfied with Depo-Provera. Only one subject 
reported being very dissatisfied with Depo-Provera. 
Thirteen subjects (93%) said that they would consider 
using Depo-Provera in the future. One subject (7%) stated 
that she would not consider using Depo-Provera in the 
future.
The last question on the questionnaire was an 
optional question which asked the subject to list three 
things that she liked most about Depo-Provera and three 
things which she liked least about Depo-Provera. Three 
common responses to what was liked most about Depo-Provera 
were "only have to take it every three months" (n = 5),
"no periods" (n= 4), and "it's very effective" (n = 3).
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Other responses about what was liked best about Depo- 
Provera were as follows:




The most commonly cited responses to what the 
subjects like least about Depo-Provera were "spotting" (n 
= 4) and "periods too long" (n = 4). The following 
responses were reported by three subjects: "eat a lot," 
"gain weight," and "headaches." Responses made by 2 
subjects were "hate needles" and "dizziness." One subject 
responded with a complaint of a "stiff arm."
Most of the adolescents who responded to the 
questionnaire were over the age of 18 years. Eleven of the 
subjects were African Americans, and almost half of the 
subjects had been pregnant at least one time. Of those who 
had been pregnant, the majority had been pregnant one time 
and had one living child. Only one subject who had been 
pregnant reported having no living child. Half of the 
subjects reported previously using oral contraceptive
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pills, condoms, or both. Three subjects had never used any 
birth control method before beginning Depo-Provera.
Over three quarters of the sample chose Depo-Provera 
because it was required only every 3 months. Other common 
reasons reported for choosing Depo-Provera were because 
the medication was effective, inexpensive or free, and 
inconspicuous. Depo-Provera had been in use by the 
subjects from 3 months to 3 years. The majority of the 
subjects had used Depo-Provera for 12 months.
Only 2 subjects were no longer using Depo-Provera. 
Both of the subjects who no longer used Depo-Provera 
reported that they discontinued use of the method because 
of physical and menstrual symptoms. Only one subject was 
very dissatisfied with Depo-Provera; the remaining 
subjects were very satisfied or somewhat satisfied. Only 
one subject said that she would never consider using Depo- 
Provera in the future.
Responses about three things liked most and three 
things liked least about Depo-Provera yielded many 
differing responses. The most common responses to what was 
liked most about Depo-Provera were "only have to take it 
every three months," "no periods," and "it's very 
effective." The most common responses to what was liked
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least about Depo-Provera were "spotting," "periods too 
long," "eat a lot," "gain weight," and "headaches."
We, as family nurse practitioners, may be the first 
contact many young adolescent females make to aid them 
with their initial family planning assessment. By becoming 
familiar with their perceptions about Depo-Provera, we can 
educate them about the good points of using Depo-Provera 
as well as teach them about the possible side effects 
experienced with Depo-Provera. By being diligent in our 
teaching about possible side effects and utilizing methods 
to reduce side effects, we, as nurse practitioners, may be 
able to increase the number of adolescents who choose 




Adolescent pregnancy and birth rates in the United 
States are the highest of any developing country (Spitz et 
al., 1996). Although there are many contraceptive options 
available to adolescents, unplanned pregnancies among 
adolescents continue to occur. The purpose of this study 
was to observe, describe, and document the factors which 
influence the choice of and discontinuation of Depo- 
Provera as a contraceptive method as identified by 
adolescents. Becker's Health Belief Model served as the 
theoretical framework for this descriptive study. The 
research questions for this study were as follows : What 
are the factors which influence the choice of Depo-Provera 
as a contraceptive method as identified by adolescents and 
what are the factors which influence the discontinuation 
of Depo-Provera as a contraceptive method as identified by 
adolescents?
The convenience sample consisted of 14 adolescent 
females who received health care at a local state health
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department and at a local pediatric clinic in Northeast 
Mississippi. The instrument utilized for the collection of 
data was the McCarter Depo-Provera Questionnaire. 
Descriptive statistics were generated to describe the 
factors which influence adolescents' choice of and 
discontinuation of Depo-Provera as a contraceptive. 
Responses to the instrument were analyzed using frequency 
distributions and percentages.
A summary and discussion of the findings of this 
study are presented in this chapter. The conclusions, 
implications for nursing, and recommendations which 
emerged from these findings also are discussed.
Summary of.. Findings
Demographics of-the sample. The sample for this study 
consisted of 14 adolescent females between the ages of 15 
years and 2 0 years who responded to the McCarter Depo- 
Provera Questionnaire. The majority of the sample (79%) 
were African American. Eleven of the subjects (79%) had 
used some form of birth control method in the past. Six 
subjects had been pregnant and of those five reported 
having living children. Those subjects who reported 
previous pregnancies had used the pill and/or condoms.
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Only 3 subjects reported never having used any method of 
contraceptive before beginning Depo-Provera.
Use of Depo-Provera. Most of the subjects (86%) 
reported choosing Depo-Provera because they only had to 
remember it every 3 months. Over half of the sample (57%) 
had used Depo-Provera for 12 months or longer. Of those 
who discontinued use of Depo-Provera, physical and 
menstrual symptoms were the causes for discontinuation. 
Ninety-three percent of the subjects were satisfied with 
Depo-Provera and stated that they would use the method in 
the future.
Discussion
The findings of this study indicated that the 
majority of the adolescents (93%) were satisfied with 
Depo-Provera. Most of the subjects (86%) chose Depo- 
Provera because they only had to remember to get an 
injection every 3 months. Only 3 subjects had never used 
contraception before beginning Depo-Provera. Those who had 
utilized another method of birth control had used oral 
contraceptive pills, condoms, or both. Almost half of the 
subjects (43%) had previously been pregnant. The subjects 
(n = 2) who had discontinued use of Depo-Provera 
attributed discontinuation to physical and menstrual
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symptoms. Only one subject stated that she would never 
consider using Depo-Provera in the future.
In a similar study, Freda et al. (1996) found that 
dissatisfaction with oral contraceptives was the typical 
reason given for choosing Depo-Provera. Seventy-eight 
percent of the women interviewed expressed satisfaction 
with the method, and 64% planned to continue use of Depo- 
Provera. The most common reason provided for termination 
of Depo-Provera was a scheduled tubal ligation. Sixty-five 
respondents experienced side effects. The most commonly 
reported side effects included amenorrhea, headaches, hair 
loss, irregular periods, and heavy bleeding. The 
respondents did not perceive the side effects serious 
enough to prevent use of Depo-Provera. In the present 
study, 7 subjects had previously used the pill, and all 
but one subject chose Depo-Provera because they only had 
to remember it every 3 months. Those subjects who 
discontinued Depo-Provera attributed discontinuation to 
physical and menstrual problems. Ninety-three percent of 
the subjects were satisfied with Depo-Provera and would 
consider using the method in the future.
Westfall et al. (1996) found that the one-year 
continuation rate for Depo-Provera among women who
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participated in their study was only 23%. Of the women who 
received a first injection, only 57% returned for their 
next visit. The intervisit continuation rate increased to 
63% between the second and third visits. The continuation 
rate increased to 65% between the third and fourth visits. 
These researchers found no statistically significant 
difference in continuation rates based on clinical site, 
age, ethnicity, or payment type. The main reason reported 
for terminating use of Depo-Provera was difficulty 
tolerating side effects. Because the majority of the 
subjects in the present study had used Depo-Provera for 12 
months or longer, it is possible that discontinuation 
rates were not as high in this study as in the study 
conducted by Westfall et al. because their study began 
when the women were receiving their first injection. 
Westfall et al. (1996) did see an increase in continuation 
rates with each injection.
In another comparable study, Davidson et al. (1997) 
found that within the first year of use, the majority of 
the women in their study discontinued use of Depo-Provera. 
More than half of the women discontinued use after the 
first injection. Discontinuation was attributed by a 
majority of the women to side effects, such as amenorrhea.
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irregular bleeding, weight gain, headaches, mood changes, 
or acne. Thirty-one percent of the subjects were teenagers 
and were found to be at significantly greater risk for 
unintended pregnancy after discontinuation of Depo- 
Provera. The 9-month cumulative pregnancy rate of these 
teenagers who never or only occasionally used 
contraception after discontinuation of Depo-Provera was 
53%. This study, unlike the present study, followed women 
during their first year of use of Depo-Provera. Because 
the present study consisted largely of a sample of 
adolescents who had been on Depo-Provera for 12 months or 
longer, the continuation rates may have been higher due to 
the number of previous injections received by the 
adolescents.
The Health Belief Model provided the theoretical 
framework for this study. This theory uses 
sociopsychological variables in the explanation of 
preventive health behavior. The Health Belief Model has 
been shown by current research to be a value expectancy 
approach to explaining and predicting health behaviors 
that go beyond straight information giving. This approach 
can be used to intervene in encouraging contraceptive use 
among adolescents. Because contraceptive action involves a
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preventive health decision followed by correct and 
consistent use, the model may have useful applications to 
both the prevention and compliance aspects of 
contraceptive behavior (Zellman, 1984). Individual 
perceptions of adolescents related to their perceived 
susceptibility to pregnancy are important. Modifying 
factors include the adolescents' knowledge about pregnancy 
prevention, the types of contraceptives, the availability 
of contraceptives, and the consequences of pregnancy. The 
likelihood of action includes the adolescents' perceived 
benefits of a long-acting contraception as well as 
perceived side effects of use with this type of 
contraceptive.
Limitations
The limitations of this study were internal as well 
as external. A lack of randomization was the greatest 
threat to generalization of this study's findings. Sample 
selection was restricted to the number of subjects who 
responded to the questionnaire. The sampling design was 
one of convenience from only two clinics ; therefore, a 
true representation of adolescents who use Depo-Provera 
must be questioned. The subjects were required to have 
parental consent to participate in the study if they were
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age 18 years or younger, even though parental consent was 
not needed for them to receive the Depo-Provera injection. 
This researcher believes that the need for parental 
consent for participation in the study had a negative 
effect on participation in the study. The instrument was 
researcher-designed and had only face validity.
Conclusions
The following conclusions were derived from the 
findings of this study :
1. The majority of the adolescents had used another 
method of birth control before using Depo-Provera.
2. Almost half of the adolescents had been pregnant 
before using Depo-Provera.
3. The adolescents chose Depo-Provera because they 
only had to remember it every 3 months.
4. Most of the adolescents had used Depo-Provera for 
12 months or longer.
5. Generally adolescents are satisfied with Depo- 
Provera.
6. The majority of the subjects in this study would 
use Depo-Provera in the future.
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Implications for Nursing
Adolescent pregnancy is a national dilemma that 
transcends the boundaries of socioeconomic class, race, 
and ethnicity. Adolescent pregnancy has negative 
consequences for both mother and child ("Teen Pregnancy," 
1997) . Nearly 60% of all pregnancies in the United States 
are unintended, and almost one half of these occurred 
because contraception failed or was not used properly 
(Marble, 1996). Adolescent girls who become pregnant are 
more likely to be poor and have limited future 
possibilities. Pregnant teens also are less likely to seek 
prenatal care and more likely to have medical problems 
during their pregnancy ("Teen Pregnancy," 1997) .
This study identified some of the characteristics of 
adolescent girls who chose Depo-Provera. In this study, 
the adolescents were half as likely to have previously 
used another method of birth control and have experienced 
a pregnancy. These adolescents chose Depo-Provera because 
of the convenience of receiving an injection only once 
every 3 months, because this method is inconspicuous to 
others, because of the effectiveness of the method, and 
because the injection was inexpensive or free. Only 2 of 
the adolescents in this study had experienced side effects
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which they perceived severe enough to discontinue Depo- 
Provera, All but one of the subjects were satisfied with 
Depo-Provera and would consider using Depo-Provera in the 
future.
This study sought to improve the knowledge base of 
nurse practitioners as to the factors that influence 
adolescents' choice of Depo-Provera for contraception as 
well as the factors that influence their discontinuation 
of Depo-Provera. By understanding the factors that 
influence adolescents to choose Depo-Provera, nurse 
practitioners can speak to potential users about the 
benefits. Conversely, by being familiar with factors that 
lead to discontinuation of Depo-Provera, nurse 
practitioners can counsel adolescents about these factors 
in an attempt to increase compliance with this very 
effective method of contraception. By encouraging 
adolescents to choose Depo-Provera and counseling them on 
the possible side effects, compliance may be increased 
which could in turn lead to a decrease in adolescent 
pregnancy.
Recommendations for Further Study
Based on the findings of this study, the following 
recommendations are made for future research in nursing:
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1. Replication of the study with a larger, more 
diverse sample.
2. Replication of the study without parental consent 
for participation in the study if not required for 
administration of Depo-Provera.
3. Conduction of research to include past sexual 
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1. How old are you?
  13 years   17 years
  14 years   18 years
  15 years   19 years
  16 years ____ 2 0 years
2. What is your race?
  Caucasian
  African-American




3. Have you ever been pregnant?
  Yes (if yes, how many times?)_______
  No
4. How many living children do you have?_____
5. What other methods of birth control have you used? 
(Please check all that apply)
  The pill
  Condom
  Spermicidal foam or cream
  Condom with spermicidal foam or cream
  Norplant
 - lUD
  Other method (please specify)_________________
Why did you choose Depo-Provera? (Please check all 
that apply)
  Only have to remember it every 3 months
  Very effective
  Inexpensive or free
  No one can tell I'm using it
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7. How long have you used Depo-Provera?__________________
8. If you no longer use Depo-Provera, why did you stop 
using Depo-Provera? (Please check all that apply)
  Physical symptoms (nausea, dizziness, weight
gain, headaches, hair loss, fatigue, breast 
tenderness, acne or other skin problems, or 
facial hair)
  Menstrual problems (vaginal discharge, irregular
periods, spotting between periods, or no 
periods)
  Mental problems (nervousness, anxiety, or
depression)
  Other (please specify)____________________________
9. How satisfied were you with Depo-Provera?
  Very satisfied
  Somewhat satisfied
  Neither satisfied nor dissatisfied
  Somewhat dissatisfied
  Very dissatisfied




11. Please list 3 things you like most and 3 things you 
like least about Depo-Provera. (Optional)
Like most Like least
a. _________________________ a. _____________________
b. _________________________ b. _____________________
c. _________________________ c. _____________________
APPENDIX B
APPROVAL OF THE COMMITTEE ON USE OF 
HUMAN SUBJECTS IN EXPERIMENTATION OF 
MISSISSIPPI UNIVERSITY FOR WOMEN
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( 6 0 1 ) 3 2 9 - 7 1 4 2
( Oliinthii ' , .  M S  v r n i
April 8, 1998
Ms. Carey E. McCarter
c/o Graduate Program in Nursing
Campus
Dear Ms. McCarter:
I am pleased to inform you that the members of the Committee 
on Human Subjects in Experimentation have approved your proposed 
research as submitted provided any participant under the age of 18 
has consent from a parent or guardian. The Committee does not fee 
that age 16 is a proper age.
I wish you much success in your research.
Sincerely,




cc: Mr. Jim Davidson
Dr. Mary Pat Curtis 
Dr. Bonnie Lockard






12 9 Point Harbor Drive 
West Point, MS 39773
April 20, 1998 
To: (Clinic)
Dear __________
I am a graduate student at Mississippi University for Women in 
Columbus, Mississippi, pursuing a Master of Science in Nursing with a 
specialty as a Family Nurse Practitioner. My anticipated date of 
graduation is August 1998.
As a requirement for graduation, I am conducting a research study to 
determine the factors which influence adolescents' choice of and 
discontinuation with Depo-Provera as a contraceptive. I would like to
distribute the McCarter Depo-Provera Questionnaire to patients at your
clinic who are currently using or who have used Depo-Provera as a 
means of contraception. Attached for your review is a copy of the
McCarter Depo-Provera Questionnaire, the subject's Consent to 
Participate, and a Parental or Guardian Consent, if required. The 
questionnaire takes approximately 1 to 2 minutes to complete. All data 
obtained from the questionnaire will be kept strictly confidential.
I would very much appreciate your consideration of this matter. You 
can reach me at (601) 494-7720 or (601) 244-1190 if you have any 
questions regarding this study. I will be happy to answer any 
questions over the telephone or arrange a personal meeting to discuss 
any issues that you might have.
Please sign below if you grant permission for distribution of the 
McCarter Depo-Provera Questionnaire to patients of your clinic. A 
return envelope is enclosed for your convenience.




Carey E. McCarter, RN 
129 Point Harbor Drive 
West Point, Mississippi 39773
Aptil 29, 1998
Dr. Pimla Su11i\an, RN. C'S, DSN 
Children’s Health Center 
3491 Bhiecutt Road 
Columbus. Mississippi 39701
Dear Dr. Sullivan:
I am a graduate student at Mississippi University for Women in Columbus, Mississippi 
pursuing a Master o f Science in Nursing with a specialty as a Family Nurse Practitioner. My 
anticipated date o f graduation is August 1998.
As a requirement for graduation, I am conducting a research stud) to determine the factors 
which influence adolescents’ choice o f and discontinuation with Depo-Provera as a 
corttracepth e. I would like to distribute, by means o f  U.S. Mail, the McCarter Depo- 
Provera Questionnaire to patients o f your clinic who are currenti) using or who have utilized 
Depo-Provera as means o f contraception. Attached for ) our review is a copy o f the 
McCarter Depo-Provera Questionnaire, the subject's Consent to Participate, and a parental 
or guardian consent, if required. I he questionnaire takes approxitnatel) I to 2 minutes to 
complete. All data obtained from the questionnaire will be kept strictly confidential.
I would vety much appreciate your consideration o f this matter. You can reach me at 601- 
494-7720 or 601-244-1190 if  you have an) questions regarding this study. I will be happy 
to answer any questions over the telephone or arrange a personal meeting to discuss any 
issues that you might have.
Please sign below if you grant permission for distribution of the McCarter Depo-Provera 
Questionnaire to patients o f your clinic. A return envelope is enclosed for your convenience.




Carey E. McCaiter 
129 Point I larbor Drive 
West Point, Mississippi 39773
April 29, 1998
Office o f  Public Health Nursing 
Mississippi State Department o f Health 
P O Box 1700 
Jackson, MS 39215
Dear Sir:
I am a graduate studetit at Mississippi Universit)' for Women in Columbus, Mississippi 
pursuing a Master o f Science in Nursing with a specialty as a Family Nurse Practitioner.
My anticipated date o f  graduation is August 1998.
/\s a requirement for graduation, I am conducting a research study to determine the factors 
which influence adolescents’ choice o f and discontinuation with Depo-Provera as a 
contraceptive. I would like fo distribute by means o f U.S. Mail, the McCarter Depo- 
Provera Questionnaire to patients at the l owndes Count) Health Department in Coulmbus 
who are current!)- using or who have utilized Depo-Provera as means o f contraception. 
Included for your review are a copy o f materials submitted for approval by the Committee 
on the Use o f Human Subjects in Experimentation at Mississippi Universitv for Women, a 
copy o f the McCarter Depo-Provera Questionnaire, a copy o f  the subject’s Consent to 
Participate, and a copy o f the Parental or Guardian Consent Form. The questionnaire 
takes approximately 1 to 2 minutes to complete. All data obtained from the questionnaire 
will be kept strictly confidential.
I would very much appreciate your consideration o f this matter. Please call me at 601-494- 
7720 if you hav e any questions regarding tliis study. 1 will be happy to answer any 
questions over the telephone or arrange a personal meeting to discuss any issues that you 
miglit have.
Please sign below if you grant permission for distribution o f the McCarter Depo-Provera 
Questionnaire at your clinic. A return envelope is enclosed for your convenience.
Representative o f l.owndes Onunty Health Dept. . Date 






If you are 18 years old or younger and have never been 
pregnant, parental or guardian consent is required for 
participation in this study.
Dear Participant,
My name is Carey McCarter. I am a registered nurse currently 
enrolled at Mississippi University for Women. As part of the 
requirements for graduation from the Master of Science in 
Nursing program, I am conducting a research study. The purpose 
of the study is to determine the factors which influence choice 
of and discontinuation with Depo-Provera among adolescents.
This information will be helpful in discovering ways in which 
any adverse side effects may be reduced or eliminated. All 
information reflected on the questionnaire will be 
confidential. I am the only person who will see the 
questionnaire, and it will be destroyed after analysis of data. 
To assure your anonymity, please do not write your name on the 
questionnaire or the return envelope.
Participation in this study is on a voluntary basis, and your 
participation in this study will not affect your health care 
services. If you are between the ages of 13 and 18 years and 
have never been pregnant, parental or guardian consent is 
required for participation in this study. Please have your 
parent or legal guardian sign the enclosed consent form. By 
signing below, you are agreeing to participate in this study.
Please return the questionnaire, the Participant Consent Form, 
and the Parental or Guardian Consent Form (if required) in the 
enclosed self-addressed, stamped envelope provided. Thank you 
for your time and effort in participating in this study.
Signature of Participant Date
Signature of Researcher Date
APPENDIX E
PARENTAL OR GUARDIAN CONSENT FORM
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1 0 0
Parental or Guardian Consent Form
Dear Parent or Guardian,
My name is Carey McCarter. I am a registered nurse 
currently enrolled at Mississippi University for Women. As 
part of the requirements for graduation from the Master of 
Science in Nursing program, I am conducting a research 
study. The purpose of the study is to determine the 
factors which influence adolescents' choice of and 
discontinuation with Depo-Provera as a contraceptive. This 
information will be helpful in discovering ways in which 
any adverse side effects may be reduced or eliminated. I 
am requesting your permission to allow your child or ward 
to take part in this study by filling out the enclosed 
questionnaire. All information reflected on the 
questionnaire will be confidential. I am the only person 
who will see the questionnaire, and it will be destroyed 
after analysis of the data.
Participation in this study is on a voluntary basis, and 
participation in this study will not affect your child's 
health care services. By signing below, you are agreeing 
to allow your child or ward to participate in this study.
Please return this consent form along with the 
questionnaire and the participant consent form in the 
self-addressed, stamped envelope provided. Thank you for 
your time and effort in participating in this study.
Signature of Parent or Guardian Date






June 2, 1998 
Dear Participant,
My name is Carey McCarter. I am a registered nurse currently 
enrolled at Mississippi University for Women. As part of the 
requirements for graduation from the Master of Science in Nursing 
program, I am conducting a research study. On May 2 0*"̂ I sent to 
you a packet which contained information about the study as well 
as consent forms, the questionnaire, and a return envelope. All 
information reflected on the questionnaire will be confidential.
I am the only person who will see the questionnaire, and it will 
be destroyed after analysis of the data.
Participation in this study is on a voluntary basis. Please 
return the questionnaire, the Participant Consent Form, and the 
Parental or Guardian Consent Form (if required) in the self- 
addressed, stamped envelope provided. Your time and effort in 
participating in this study are greatly appreciated.
Sincerely,
Carey McCarter
